No­var­tis dou­bles down on neu­ro­log­ic gene ther­a­py work with Voy­ager

No­var­tis has lined up two more neu­ro­log­ic dis­eases in its gene ther­a­py col­lab­o­ra­tion with Voy­ager Ther­a­peu­tics, this time pay­ing about $100 mil­lion up­front to get its hands on cap­sids for Hunt­ing­ton’s dis­ease and spinal mus­cu­lar at­ro­phy.

The Tues­day morn­ing deal serves as a pre­cur­sor to what is like­ly to be a pact-heavy JP Mor­gan Health­care Con­fer­ence next week. Voy­ager’s shares $VY­GR were up 32% be­fore Tues­day’s open­ing bell, ris­ing to $11.21 apiece. As part of the deal, No­var­tis will buy $20 mil­lion worth of shares at $9.32 per share, Voy­ager dis­closed in an SEC fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER